Clinical Studies and Guidelines

There is a strong and growing body of clinical evidence highlighting the importance of detecting cardiac abnormalities in patients with syncope or unexplained symptoms.

Studies have demonstrated the clinical and economic value of using an insertable cardiac monitor (ICM), such as Reveal®, in the diagnosis of unexplained syncope:

General Guidelines

AHA/ACCF and ESC Guidelines*^1,2 support the use of an insertable cardiac monitor to assess symptoms possibly related to rhythm disturbances is indicated for:

(1) patients with clinical syndromes or situations at increased risk of cardiac arrhythmias

and/or

(2) patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.

For more information on the guidelines refer to:

• ACC/AHA Guidelines
• European Society of Cardiology (ESC) Guidelines

*AHA/ACCF—American Heart Association/American College of Cardiology Foundation ESC—European Society of Cardiology

¹Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the Evaluation of Syncope: From the American Heart Association Councils and the American College of Cardiology Foundation: In collaboration with the Heart Rhythm Society. Circulation. January 17, 2006;113(2):316-327. 2Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope—update 2004. Europace. November 2004;6(6):467-537.

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map